-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Chimeric -X- _ B-Intervention
antigen -X- _ I-Intervention
receptor -X- _ I-Intervention
( -X- _ I-Intervention
CAR -X- _ I-Intervention
) -X- _ I-Intervention
â€“modified -X- _ I-Intervention
T -X- _ I-Intervention
cells -X- _ I-Intervention
that -X- _ O
target -X- _ O
the -X- _ O
CD19 -X- _ O
antigen -X- _ O
present -X- _ O
a -X- _ O
novel -X- _ O
promising -X- _ O
therapy -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
relapsed -X- _ B-Patient
B-cell -X- _ I-Patient
acute -X- _ I-Patient
lymphoblastic -X- _ I-Patient
leukemia -X- _ I-Patient
( -X- _ I-Patient
B-ALL -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
Although -X- _ O
cytokine -X- _ O
release -X- _ O
syndrome -X- _ O
( -X- _ O
CRS -X- _ O
) -X- _ O
and -X- _ O
neurotoxicity -X- _ O
have -X- _ O
emerged -X- _ O
as -X- _ O
predominant -X- _ O
noninfectious -X- _ O
complications -X- _ O
of -X- _ O
CD19 -X- _ O
CAR -X- _ O
T-cell -X- _ O
therapy -X- _ O
, -X- _ O
infections -X- _ O
associated -X- _ O
with -X- _ O
this -X- _ O
treatment -X- _ O
modality -X- _ O
have -X- _ O
not -X- _ O
been -X- _ O
well -X- _ O
documented. -X- _ O
METHODS -X- _ O
: -X- _ O
We -X- _ O
analyzed -X- _ O
infectious -X- _ O
complications -X- _ O
that -X- _ O
followed -X- _ O
CD19 -X- _ B-Intervention
CAR -X- _ I-Intervention
T-cell -X- _ I-Intervention
therapy -X- _ I-Intervention
in -X- _ O
53 -X- _ B-Patient
adult -X- _ I-Patient
patients -X- _ I-Patient
with -X- _ I-Patient
relapsed -X- _ I-Patient
B-ALL -X- _ I-Patient
enrolled -X- _ O
in -X- _ O
a -X- _ O
phase -X- _ O
I -X- _ O
clinical -X- _ O
trial -X- _ O
at -X- _ O
Memorial -X- _ O
Sloan -X- _ O
Kettering -X- _ O
Cancer -X- _ O
Center -X- _ O
( -X- _ O
NCT01044069 -X- _ O
) -X- _ O
. -X- _ O
RESULTS -X- _ O
: -X- _ O
Overall -X- _ O
, -X- _ O
22 -X- _ B-Outcome
patients -X- _ I-Outcome
( -X- _ I-Outcome
42 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
experienced -X- _ I-Outcome
26 -X- _ I-Outcome
infections -X- _ I-Outcome
( -X- _ I-Outcome
17 -X- _ I-Outcome
bacterial -X- _ I-Outcome
, -X- _ I-Outcome
4 -X- _ I-Outcome
fungal -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
5 -X- _ I-Outcome
viral -X- _ I-Outcome
) -X- _ I-Outcome
within -X- _ I-Outcome
the -X- _ I-Outcome
first -X- _ I-Outcome
30 -X- _ I-Outcome
days -X- _ I-Outcome
of -X- _ I-Outcome
CAR -X- _ I-Outcome
T-cell -X- _ I-Outcome
infusion. -X- _ I-Outcome
In -X- _ I-Outcome
10 -X- _ I-Outcome
of -X- _ I-Outcome
32 -X- _ I-Outcome
( -X- _ I-Outcome
31 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
patients -X- _ I-Outcome
in -X- _ I-Outcome
whom -X- _ I-Outcome
complete -X- _ I-Outcome
remission -X- _ I-Outcome
was -X- _ I-Outcome
achieved -X- _ I-Outcome
, -X- _ I-Outcome
15 -X- _ I-Outcome
infections -X- _ I-Outcome
developed -X- _ I-Outcome
between -X- _ I-Outcome
days -X- _ I-Outcome
31 -X- _ I-Outcome
and -X- _ I-Outcome
180 -X- _ I-Outcome
; -X- _ I-Outcome
the -X- _ I-Outcome
majority -X- _ I-Outcome
of -X- _ I-Outcome
these -X- _ I-Outcome
late -X- _ I-Outcome
infections -X- _ I-Outcome
were -X- _ I-Outcome
due -X- _ I-Outcome
to -X- _ I-Outcome
respiratory -X- _ I-Outcome
viruses. -X- _ I-Outcome
In -X- _ I-Outcome
general -X- _ I-Outcome
, -X- _ I-Outcome
bacterial -X- _ I-Outcome
, -X- _ I-Outcome
fungal -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
viral -X- _ I-Outcome
infections -X- _ I-Outcome
were -X- _ I-Outcome
detected -X- _ I-Outcome
at -X- _ I-Outcome
a -X- _ I-Outcome
median -X- _ I-Outcome
of -X- _ I-Outcome
18 -X- _ I-Outcome
, -X- _ I-Outcome
23 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
48 -X- _ I-Outcome
days -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
, -X- _ I-Outcome
after -X- _ I-Outcome
CAR -X- _ I-Outcome
T-cell -X- _ I-Outcome
infusion. -X- _ I-Outcome
CRS -X- _ I-Outcome
grade -X- _ I-Outcome
3 -X- _ I-Outcome
or -X- _ I-Outcome
higher -X- _ I-Outcome
was -X- _ I-Outcome
independently -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
increased -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
subsequent -X- _ I-Outcome
infection -X- _ I-Outcome
( -X- _ I-Outcome
adjusted -X- _ I-Outcome
hazard -X- _ I-Outcome
ratio -X- _ I-Outcome
[ -X- _ I-Outcome
HR -X- _ I-Outcome
] -X- _ I-Outcome
, -X- _ I-Outcome
2.67 -X- _ I-Outcome
; -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.05 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
particular -X- _ I-Outcome
with -X- _ I-Outcome
bloodstream -X- _ I-Outcome
infection -X- _ I-Outcome
( -X- _ I-Outcome
adjusted -X- _ I-Outcome
HR -X- _ I-Outcome
, -X- _ I-Outcome
19.97 -X- _ I-Outcome
; -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
.001 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Three -X- _ I-Outcome
of -X- _ I-Outcome
53 -X- _ I-Outcome
patients -X- _ I-Outcome
( -X- _ I-Outcome
6 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
died -X- _ I-Outcome
of -X- _ I-Outcome
an -X- _ I-Outcome
infection-related -X- _ I-Outcome
cause. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Infections -X- _ O
in -X- _ O
adult -X- _ O
patients -X- _ O
with -X- _ O
relapsed -X- _ O
B-ALL -X- _ O
are -X- _ O
common -X- _ O
after -X- _ O
CD19 -X- _ O
CAR -X- _ O
Tcell -X- _ O
therapy. -X- _ O
Understanding -X- _ O
the -X- _ O
infectious -X- _ O
complications -X- _ O
that -X- _ O
are -X- _ O
temporally -X- _ O
coincident -X- _ O
with -X- _ O
CD19 -X- _ O
CAR -X- _ O
T-cell -X- _ O
therapy -X- _ O
is -X- _ O
critical -X- _ O
for -X- _ O
developing -X- _ O
effective -X- _ O
prophylactic -X- _ O
and -X- _ O
other -X- _ O
supportive -X- _ O
care -X- _ O
measures -X- _ O
to -X- _ O
improve -X- _ O
clinical -X- _ O
outcomes. -X- _ O
CLINICAL -X- _ O
TRIALS -X- _ O
REGISTRATION -X- _ O
: -X- _ O
NCT01044069 -X- _ O
. -X- _ O

